Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU. A retrospective, observational, pilot study of 36 children...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric Rheumatology 2023-12, Vol.21 (1), p.148-148, Article 148
Hauptverfasser:	Dehoorne, Jo L, Groth, Helena, Carlé, Emma, De Schrijver, Ilse, Sys, Celine, Delbeke, Patricia, Kreps, Elke O, Renson, Thomas, Bonroy, Carolien
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Adalimumab - therapeutic use Anti-Inflammatory Agents - therapeutic use Antibodies Biological products Care and treatment Child Communications equipment Comparative analysis Drug dosages Health aspects Humans Inflammation Inflammatory diseases Medical imaging Medical records Monoclonal antibodies Pediatric noninfectious uveitis Pediatrics Pilot Projects Precision Medicine Retrospective Studies Rheumatology Therapeutic drug monitoring Therapeutic range Treatment Outcome Trough levels Tumor necrosis factor Uveitis Uveitis - drug therapy Visual acuity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU. A retrospective, observational, pilot study of 36 children with NIU aged
ISSN:	1546-0096 1546-0096
DOI:	10.1186/s12969-023-00928-2